SillaJen Inc - Asset Resilience Ratio

Latest as of September 2025: 50.41%

SillaJen Inc (215600) has an Asset Resilience Ratio of 50.41% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SillaJen Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩62.70 Billion
≈ $42.49 Million USD Cash + Short-term Investments

Total Assets

₩124.38 Billion
≈ $84.29 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how SillaJen Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is SillaJen Inc's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down SillaJen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 215600 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩62.70 Billion 50.41%
Total Liquid Assets ₩62.70 Billion 50.41%

Asset Resilience Insights

  • Very High Liquidity: SillaJen Inc maintains exceptional liquid asset reserves at 50.41% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

SillaJen Inc Industry Peers by Asset Resilience Ratio

Compare SillaJen Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Dianthus Therapeutics Inc.
NASDAQ:DNTH
Biotechnology 63.98%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 62.24%
Damora Therapeutics, Inc.
NASDAQ:DMRA
Biotechnology 0.00%
Wecome Pharmaceutical Co Ltd
SHE:300878
Biotechnology 0.67%
Tectonic Therapeutic, Inc.
NASDAQ:TECX
Biotechnology 86.66%
Relmada Therapeutics Inc
NASDAQ:RLMD
Biotechnology 95.25%
MediWound Ltd
F:M8W
Biotechnology 56.04%

Annual Asset Resilience Ratio for SillaJen Inc (2016–2024)

The table below shows the annual Asset Resilience Ratio data for SillaJen Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 78.85% ₩117.51 Billion
≈ $79.63 Million
₩149.02 Billion
≈ $100.99 Million
+14.59pp
2023-12-31 64.26% ₩49.30 Billion
≈ $33.41 Million
₩76.71 Billion
≈ $51.99 Million
+3.88pp
2022-12-31 60.38% ₩62.46 Billion
≈ $42.33 Million
₩103.45 Billion
≈ $70.10 Million
-19.92pp
2021-12-31 80.30% ₩108.26 Billion
≈ $73.37 Million
₩134.83 Billion
≈ $91.37 Million
+36.77pp
2020-12-31 43.53% ₩20.64 Billion
≈ $13.99 Million
₩47.42 Billion
≈ $32.14 Million
+38.36pp
2018-12-31 5.18% ₩10.00 Billion
≈ $6.78 Million
₩193.19 Billion
≈ $130.92 Million
-9.29pp
2017-12-31 14.47% ₩34.00 Billion
≈ $23.04 Million
₩234.95 Billion
≈ $159.23 Million
-39.33pp
2016-12-31 53.80% ₩152.85 Billion
≈ $103.59 Million
₩284.13 Billion
≈ $192.55 Million
--
pp = percentage points

About SillaJen Inc

KQ:215600 Korea Biotechnology
Market Cap
$206.41 Million
₩304.58 Billion KRW
Market Cap Rank
#16514 Global
#615 in Korea
Share Price
₩2205.00
Change (1 day)
-0.68%
52-Week Range
₩1844.00 - ₩4975.00
All Time High
₩121250.15
About

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more